nCage Therapeutics S.A.

Startup Plus

nCage Therapeutics is a biotechnology company pioneering the development of next-generation vaccines through an innovative, proprietary protein nanocage platform. Founded as a spin-off from the Jagiellonian University in Kraków, Poland, nCage combines expertise in protein engineering, structural biology, and immunology to address major challenges in vaccine development.

At the core of nCage’s technology is a fully synthetic, highly customizable virus-like particle (VLP) platform based on self-assembling protein cages. These precisely engineered nanostructures enable controlled, multivalent presentation of antigens, offering opportunities to enhance immune responses while improving vaccine stability and versatility.

Unlike conventional VLPs, nCage’s platform allows flexible antigen selection, precise control over antigen density, and the incorporation of multiple antigenic components within a single particle. This modular approach supports the development of vaccines targeting conserved epitopes, potentially providing broader protection against highly variable pathogens.

nCage is currently advancing vaccine programs targeting influenza and bacterial infections, including Lyme disease, with a particular focus on overcoming antigenic variability and improving the breadth of protective immunity.

By combining rational antigen design with advanced protein nanotechnology, nCage Therapeutics aims to establish a versatile platform for developing safer, more effective, and broadly protective vaccines against challenging infectious diseases.

website